PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today. The findings suggest that PCSK9 inhibitors, a new class ...
The recent approval of enlicitide was seen as a boon for some clinical scenarios, although real-world impact remains to be ...
High levels of low-density lipoproteins, parcels of lipids and protein that carry cholesterol, are a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by ...
This study is led by professor Jingsong Ou(Division of Cardiac Surgery, Cardiovascular Diseases Institute, The First Affiliated Hospital, Sun Yat-sen University) and professor Zhi-Jun Ou (Division of ...
Elevated proprotein convertase subtilisin/kexin type 9 (PCSK9) levels have been associated with adverse outcomes in patients hospitalized for sepsis. PCSK9 loss-of-function (LOF) variants area ...
A new case-control genetic study is reassuring in finding no association between a genetic proxy for pharmacologic PCSK9 inhibition and either heart failure or adverse cardiac remodeling in a large ...
High levels of low-density lipoproteins, parcels of lipids and protein that carry cholesterol, are a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by ...
A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, and key dietary tweaks—plus insights on benefits, risks, and mechanisms ...
Barcelona, Spain - 27 Aug 2017: PCSK9 is a co-activator of platelet function beyond its role in cholesterol homeostasis, according to research presented at ESC Congress today.1 The findings suggest ...
High LDL a leading risk factor for heart disease. Many cholesterol medications lower LDL, some of them by targeting the protein PCSK9. Scientists now report on an investigation into why experiments on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results